The fact that the stem cells originate from a muscle microbiopsy and are produced to GMP standards allows the teams to carry out a rapid transfer to the clinic.
Within the general framework of reducing animal experimentation, Revatis offers undifferentiated or differentiated cells to partners involved in the production of organs on a chip or organoids. Once the models are finalized, Revatis proposes to produce the patient's own cells in order to obtain personalized organs on a chip or organoids.
Tissue engineering is developing rapidly, whether from decellularized organs or through 3D bioprinting. Revatis is able to provide, from a muscle micro-biopsy, several hundred million multipotent stem cells with a high differentiation potential.
Revatis is conducting veterinary clinical studies to obtain marketing authorization for innovative cellular products.